Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Raylene M, Rospond"'
Autor:
American College of Clinical Pharmacy, Raymond W. Hammond, Amy H. Schwartz, Marla J. Campbell, Tami L. Remington, Susan Chuck, Melissa M. Blair, Ann M. Vassey, Raylene M. Rospond, Sheryl J. Herner, C. Edwin Webb
Publikováno v:
Pharmacotherapy. 23:1210-1225
Since publication of the initial ACCP position statement on CDTM by pharmacists in 1997, the public, government, and much of the health care community at large have come to better appreciate the growing complexity of providing effective and safe drug
Autor:
Jill S. Burkiewicz, Raylene M. Rospond, Eric G. Boyce, Barbara G. Wells, Eric J. MacLaughlin, Joseph A. Barone, Mark R. Haase, Eunice P. Chung, Stephen W. Durst, Lingtak Neander Chan, Alissa R. Segal
Publikováno v:
Pharmacotherapy. 29:124-126
Autor:
Raylene M. Rospond
Publikováno v:
Cancer Practice. 7:317-320
Autor:
Raylene M. Rospond
Publikováno v:
Journal of the American Pharmaceutical Association (1996). 36:655-660
Tobacco and diet account for almost two-thirds of all cancer-related deaths and are among the most correctable risk factors. Up to 35% of cancer-related deaths could be avoided if appropriate screening measures were used. Research on the use of vacci
Autor:
Charles L. Loprinzi, Claudia Johnson, Robert A. Nelimark, John C. Michalak, Joseph E. Oesterling, Tammy Fischer, Walter W. Bate, Judith R. O'Fallon, Susan K. Quella, Raylene M. Rospond, Alan K. Hatfield, Ann Marie Dose, Nancy E. Klatt
Publikováno v:
New England Journal of Medicine. 331:347-352
Vasomotor hot flashes are a common symptom in women during menopause and in men who have undergone androgen-deprivation therapy for prostate cancer. Although treatment with estrogens in women and androgens in men can attenuate these symptoms, these h
Autor:
Charles L. Loprinzi, Dean H. Gesme, Richard M. Goldberg, Steven A. Kuross, Judith R. O'Fallon, Raylene M. Rospond, James B. Gerstner, Charles D. Cobau
Publikováno v:
Journal of Clinical Oncology. 12:1121-1125
PURPOSE Hydrazine sulfate is a controversial agent that was originally studied in cancer patients approximately 20 years ago. Based on a series of recent trials that suggested that this drug might have utility in cancer patients, we conducted this st
Autor:
Eric G, Boyce, Jill S, Burkiewicz, Mark R, Haase, Eric J, MacLaughlin, Alissa R, Segal, Eunice P, Chung, Lingtak-Neander, Chan, Raylene M, Rospond, Joseph A, Barone, Stephen W, Durst, Barbara G, Wells
Publikováno v:
Pharmacotherapy. 29(1)
Autor:
Miriam A. Mobley Smith, Bonnie K. Brown, Scott M. Mark, Debbie C. Byrd, Elizabeth A. Sheaffer, Gireesh V. Gupchup, Raylene M. Rospond
To identify the variables associated with an academic pharmacy career choice among the following groups: final professional-year doctor of pharmacy (PharmD) students, pharmacy residents, pharmacy faculty members within the first 5 years of academic e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b952b50746c31d6cc141bb10ad24f540
https://europepmc.org/articles/PMC2508718/
https://europepmc.org/articles/PMC2508718/
Autor:
Susan M. Meyer, Wayne T. Harris, Robert M. Levin, Todd D. Sorenson, Arlene A. Flynn, Kenneth W. Miller, Raylene M. Rospond, Wayne Kradjan, William J. Millard, Patrick S. Callery, Julie M. Ganther, Jeanne V. Goode, William T. Beck, Marialice S. Bennett, Jamie C. Barner, Pamela J. Sims, Marie A. Chisholm, Brian L. Crabtree, Richard J. Bridges, Ralph J. Altiere, Anne Y. Lin, Raymond C. Love
Publikováno v:
American Journal of Pharmaceutical Education. 67:S05
Anne Y. Lin, Ralph J. Altiere, Wayne T. Harris, Pamela J. Sims, Julie M. Ganther, Susan M. Meyer, Wayne A. Kradjan, Marialice Bennett, Brian L. Crabtree, Jeanne V. Goode, Raymond C. Love, Raylene M. Rospond, Todd D. Sorenson, Arlene A. Flynn, Patrick
Autor:
John C. Michalak, Mary B. Wilwerding, Pat Fidler, Charles L. Loprinzi, Judith R. O'Fallon, James A. Mailliard, Raylene M. Rospond, Nicholas F. Reuter, Angela W. Miser, Julie E. Hammack
Publikováno v:
Journal of pain and symptom management. 12(4)
We performed an open-label pilot study to define analgesic efficacy, acceptability, and toxicity of transdermal fentanyl in an ambulatory population of patients with cancer pain. Our 7-day study included 35 patients, all of whom had failed a trial of